Entrepreneurial
Journey

Every account of Sun Pharma begins with the same striking detail: a ₹10,000 loan, five products, two salespeople. The detail is accurate, but on its own it explains nothing. Thousands of small Indian pharmaceutical companies were founded on comparable terms in the same decade and did not survive. What distinguished this one was the choice of where to begin.

Shanghvi entered psychiatry. In early-1980s India that was a marginal therapeutic area: relatively few specialists, modest total prescription volume, and no interest from the large domestic companies whose sales forces were deployed against antibiotics, analgesics and vitamins. For a company with two salespeople, however, those characteristics were advantages rather than obstacles.

• A reachable prescriber base. The number of practising psychiatrists in India was small enough that a two-person team could actually meet a meaningful proportion of them.
• Chronic prescribing. Psychiatric medication is typically taken over long periods, producing repeat demand rather than one-off sales.
• Weak incumbent attention. Larger competitors were not defending the segment, so early share could be won without a price war.
• Brand durability. In a therapy where switching carries clinical risk, prescriber loyalty is unusually persistent.

By 1988 the model had been validated well enough to be repeated. Sun Pharma entered cardiology with Monotrate and Angize — again a specialist prescriber base, again chronic therapy, again defensible brands. The pattern that would govern the next thirty years was set: identify a therapy where depth beats breadth, take a defensible position, and then move to the next one.

A formulation company that buys its active ingredients is, in effect, renting its cost base. Its margins move with its suppliers’ prices; its quality depends on their quality; its ability to supply depends on their reliability. For a company intending eventually to sell into regulated markets, that dependence is also a regulatory exposure.

Sun Pharma addressed this early. It commissioned its own active-pharmaceutical-ingredient plant at Panoli in 1995 and acquired an existing bulk-drug facility at Ahmednagar from Knoll Pharmaceuticals in 1996. In the same period it built research capability — a first research centre in 1991, a further facility in Mumbai in 1997 — and extended manufacturing with new formulation units at Silvassa in 1998, Dadra in 2001 and Jammu in 2004.

This is the least visible phase of the company’s history and arguably the most consequential. Vertical integration is unglamorous and capital-hungry, and it produces no immediate revenue. It is also what made the next chapter possible: a company that controls its ingredients, its plants and its documentation can credibly present itself to a foreign regulator.

Sun Pharma’s international expansion followed a consistent logic: it entered markets by acquiring an existing licensed operation rather than by building one, and it preferred assets that were underperforming and therefore cheap.

The first was Caraco Pharmaceutical Laboratories of Detroit in 1997. Caraco was small, loss-making and difficult, and the relationship absorbed management attention for years. But it placed Sun Pharma inside the United States regulatory system with a manufacturing site, approvals and staff — a position that would have taken far longer to build from scratch.

The pattern repeated. In 2005 the company completed a manufacturing buyout at Bryan, Ohio and acquired ICN’s Hungarian business. Chattem Chemicals followed in 2008. Then, in 2010, came the transaction that changed the scale of the American business: a controlling stake in Taro Pharmaceutical Industries, an Israeli dermatology specialist with plants in Israel and Canada. The acquisition was contested by Taro’s founding family and took years to settle, but it roughly doubled Sun Pharma’s United States revenue and gave it a dermatology franchise it did not previously have. DUSA Pharmaceuticals and the generics business of URL Pharma were added in 2012.

I will never risk capital, but I will risk profit. Dilip Shanghvi, interviewed by Gautam Kumra, McKinsey & Company

The distinction in that statement explains a good deal about how these transactions were financed. Sun Pharma has historically carried low debt and funded acquisitions from internal accruals and equity. A contested, multi-year acquisition such as Taro consumed profit and management time; it did not put the balance sheet at risk.

On 6 April 2014 Sun Pharma announced the acquisition of Ranbaxy Laboratories in an all-share transaction valued at approximately US$4 billion. It was an unusual deal in several respects. Ranbaxy was the more famous company — for a generation it had been the public face of Indian pharmaceuticals abroad — but it was in serious regulatory trouble in the United States, with multiple sites under import alert. Sun Pharma was buying a distressed asset of a size comparable to its own.

The Competition Commission of India approved the merger in December 2014, requiring the divestment of seven products to preserve competition. The transaction completed on 25 March 2015. Ranbaxy was delisted; Daiichi Sankyo, its Japanese owner, became a major Sun Pharma shareholder. The combined business became one of the world’s largest specialty generic companies and India’s largest pharmaceutical company by a clear margin.

What followed was harder than the deal. The company had to remediate inherited manufacturing sites, rationalise overlapping product portfolios and merge two organisations with markedly different operating cultures. And it had to do all of that while the economics of its principal export market deteriorated.

The episode is instructive because it shows the limits of the strategy that had worked until then. Depth in a therapy protects against competitors; it does not protect against a change in who does the buying. The response had to be a change in what the company sold.

Sun Pharma’s answer to generic price deflation was to move up the value chain into differentiated and innovative medicines — products protected by patents, clinical data and specialist prescribing rather than by cost. Crucially, it did so mostly by licensing and acquiring assets already close to market, rather than by lengthening its own discovery timelines.

By the financial year ended March 2026 the strategy had produced a measurable shift: global innovative-medicines revenue of US$1.42 billion, equal to 20.7 per cent of company sales, with the United States innovative business passing one billion dollars. The Organon transaction, if completed, would take Sun Pharma’s revenue to roughly US$12.4 billion and place it among the twenty-five largest pharmaceutical companies in the world.

Sources: Sun Pharma milestones and FY2026 results; Sun Pharma and Organon & Co. announcement, 26 April 2026.